Innoviva, Inc. engages in the development and commercialization of pharmaceuticals.
Excellent balance sheet and good value.
Share Price & News
How has Innoviva's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: HVE has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: HVE underperformed the German Pharmaceuticals industry which returned 13.9% over the past year.
Return vs Market: HVE underperformed the German Market which returned 8.3% over the past year.
Price Volatility Vs. Market
How volatile is Innoviva's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Innoviva undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: HVE (€13.6) is trading below our estimate of fair value (€42.29)
Significantly Below Fair Value: HVE is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: HVE is good value based on its PE Ratio (9.7x) compared to the Pharmaceuticals industry average (24x).
PE vs Market: HVE is good value based on its PE Ratio (9.7x) compared to the German market (20.7x).
Price to Earnings Growth Ratio
PEG Ratio: HVE is poor value based on its PEG Ratio (4x)
Price to Book Ratio
PB vs Industry: HVE is overvalued based on its PB Ratio (4.9x) compared to the DE Pharmaceuticals industry average (2.2x).
How is Innoviva forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HVE's forecast earnings growth (2.4% per year) is above the savings rate (-0.4%).
Earnings vs Market: HVE's earnings (2.4% per year) are forecast to grow slower than the German market (13% per year).
High Growth Earnings: HVE's earnings are forecast to grow, but not significantly.
Revenue vs Market: HVE's revenue is expected to decline over the next 3 years (-9.3% per year).
High Growth Revenue: HVE's revenue is forecast to decline over the next 3 years (-9.3% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HVE's Return on Equity is forecast to be low in 3 years time (16.6%).
How has Innoviva performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HVE has high quality earnings.
Growing Profit Margin: HVE's current net profit margins (60.3%) are lower than last year .
Past Earnings Growth Analysis
Earnings Trend: HVE has become profitable over the past 5 years, growing earnings by 63.6% per year.
Accelerating Growth: HVE's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: HVE had negative earnings growth (-60.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.3%).
Return on Equity
High ROE: Whilst HVE's Return on Equity (55.83%) is outstanding, this metric is skewed due to their high level of debt.
Return on Assets
Return on Capital Employed
How is Innoviva's financial position?
Financial Position Analysis
Short Term Liabilities: HVE's short term assets ($431.2M) exceed its short term liabilities ($5.4M).
Long Term Liabilities: HVE's short term assets ($431.2M) exceed its long term liabilities ($377.3M).
Debt to Equity History and Analysis
Debt Level: HVE's debt to equity ratio (110.2%) is considered high.
Reducing Debt: HVE had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Debt Coverage: HVE's debt is well covered by operating cash flow (68.3%).
Interest Coverage: HVE's interest payments on its debt are well covered by EBIT (18.8x coverage).
Inventory Level: HVE has a low level of unsold assets or inventory.
Debt Coverage by Assets: HVE's debt is covered by short term assets (assets are 1.1x debt).
What is Innoviva's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate HVE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate HVE's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if HVE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HVE's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: HVE is not paying a notable dividend for the German market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of HVE's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Geoff Hulme (52yo)
Mr. Geoffrey Hulme, also known as Geoff, has been Interim Principal Executive Officer of Innoviva Inc. since May 21, 2018. Prior to joining Innoviva, Mr. Hulme served as the owner and manager of Steel Vall ...
CEO Compensation Analysis
Compensation vs Market: Geoff's total compensation ($USD419.65K) is below average for companies of similar size in the German market ($USD1.62M).
Compensation vs Earnings: Insufficient data to compare Geoff's compensation with company performance.
|Independent Director||2yrs||US$453.83k||0.036% $490.8k|
|Independent Director||2.2yrs||US$302.08k||0.053% $713.8k|
|Independent Chairman of the Board||0yrs||US$307.07k||0.028% $381.9k|
|Independent Director||2yrs||US$446.96k||0.024% $328.9k|
|Independent Director||2yrs||US$441.81k||0.024% $328.9k|
Experienced Board: HVE's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Innoviva, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Innoviva, Inc.
- Ticker: HVE
- Exchange: DB
- Founded: 1996
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.463b
- Listing Market Cap: US$1.345b
- Shares outstanding: 101.30m
- Website: https://www.inva.com
Number of Employees
- Innoviva, Inc.
- 1350 Old Bayshore Highway
- Suite 400
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|INVA||NasdaqGS (Nasdaq Global Select)||Yes||Common Shares||US||USD||Oct 2004|
|HVE||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Oct 2004|
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/25 22:12|
|End of Day Share Price||2020/02/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.